Filtered By:
Drug: Simvastatin
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 124 results found since Jan 2013.
Simvastatin improves cardiac function through Notch1 activation in BALB/c mice with chronic Chagas cardiomyopathy.
Conclusions and Implications: Simvastatin, probably acting through the Notch1 pathway, decreases inflammation, improving cardiac function in chronically T. cruzi-infected mice.
PMID: 32393497 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - May 10, 2020 Category: Microbiology Authors: Guzmán-Rivera D, Liempi A, González-Herrera F, Fuentes S, Carrillo I, Abarca P, Castillo C, Kemmerling U, Pesce B, Maya JD Tags: Antimicrob Agents Chemother Source Type: research
Disease Status –Dependent Drug–Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis
Concurrent use of simvastatin (SV) and Gardenia jasminoides J. Ellis (GJ) was adopted in patients with multi-morbidity, such as stroke rehabilitation patients with NASH. Although hepatotoxicity has been reported in both of them and NASH could alter the pharmacokinetics of drugs/herbs, the interaction between SV and GJ and the related hepatotoxicity remained uninvestigated under neither healthy nor NASH condition. The current study aimed to evaluate the potential hepatotoxicity resulted from the interactions between SV and GJ in both healthy and NASH rats. Both healthy and NASH rats received two-week SV (p. o., 8.66 mg/kg,...
Source: Frontiers in Pharmacology - April 23, 2021 Category: Drugs & Pharmacology Source Type: research
A systematic review of randomized clinical trials on the efficacy and safety of pitavastatin
Conclusion The FDA proven indications of pitavastatin are primary dyslipidemia and mixed dyslipidemia as adjunctive therapy to dietary changes to lower total cholesterol, LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C. Pitavastatin might be suitable for subjects with diabetes, ACS (reduced revascularization), metabolic syndrome, CKD, HIV, and subjects with low levels of HDL-C. We highly recommend rational individualization for the selection of statin.PMID:35642121 | DOI:10.2174/2772432817666220531115314
Source: Pharmacological Reviews - June 1, 2022 Category: Drugs & Pharmacology Authors: Asim Ahmed Elnour Judit Don Azza Ramadan Adel Sadeq Abdulla Al Amoodi Kishore Gnana Sam Nadia Al Mazrouei Mohamed A Baraka Farah Hamad Farah Maisoun Alkaabi Source Type: research
Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients
ConclusionThe results of this study showed better population-level effectiveness of simvastatin compared with gemfibrozil for the primary prevention of MACE; however, a definitive randomized controlled trial is required to compare simvastatin with gemfibrozil among patients with low HDL cholesterol, as they appear to obtain benefit with gemfibrozil.
Source: Clinical Drug Investigation - October 14, 2022 Category: Drugs & Pharmacology Source Type: research
Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial
AbstractPurpose of ReviewThe Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated the clinical benefit of the combination of ezetimibe-simvastatin compared to placebo-simvastatin following acute coronary syndrome (ACS). This review highlights key findings from this study with particular attention to the practice-changing impact on guidelines for low-density lipoprotein cholesterol (LDL-C) reduction after ACS, especially among high-risk populations.Recent FindingsConsistent reductions in LDL-C have been reported with newer lipid-lowering therapies (proprotein convertase subtilisin/k...
Source: Current Atherosclerosis Reports - February 10, 2023 Category: Cardiology Source Type: research
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan
CONCLUSIONS: The use of statins was not in concordance with the guidelines. Many of the patients surveyed were undertreated and adequate follow-up to identify the extent of patients' compliance and response was missing.PMID:37401284 | DOI:10.26355/eurrev_202306_32785
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: L Gharaibeh S Al Zoubi H Sartawi D Ayyad M Al-Hawamdeh R Alrashdan Source Type: research
